F182112

F182112 · Shandong New Time Pharmaceutical Co., LTD

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for F182112, covering 2025-12-31 to 2025-12-31. Get the full timeline:

Most recent: Clinical Trial Update: A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]